Archer Materials Limited
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Archer Materials Limited (ASX:AXE; OTC:ARRXF) develops and commercializes advanced semiconductor devices and sensors for quantum computing, quantum sensing, and medical diagnostics; its core offerings include the 12CQ chip featuring room-temperature qubits based on carbon nano-onion quantum material, tunnelling magnetoresistance (TMR) sensors, and graphene-based lab-on-a-chip biochips for applications such as rapid blood potassium testing targeting hypo- and hyperkalemia detection in chronic kidney disease patients. Founded in 2007 and headquartered in Adelaide, Australia, the company operates primarily in the quantum technology and semiconductor sectors, leveraging research and development infrastructure to advance deep tech innovations for integration into modern electronics and healthcare systems. Formerly Archer Exploration Limited, it rebranded to Archer Materials Limited in October 2019 to reflect its pivot from mineral exploration to materials science and quantum technologies. Recent developments include a July 2025 breakthrough in on-chip electrical detection of magnetic resonance (EDMR) advancing the 12CQ qubit project toward a mid-2026 demonstration, a strategic partnership with Emergence Quantum announced in October 2025 to accelerate joint research, development, and commercialization of quantum technologies, and co-development with EPFL of a single-chip integrated pulsed electron spin resonance microsystem alongside miniaturization of its graphene FET biochip design. The company scheduled its 2025 Annual General Meeting for November 20, 2025, including director re-elections, underscoring ongoing governance and strategic focus amid progress in qubit and biochip milestones supported by government funding initiatives.
Percheron Therapeutics targets one of oncology’s toughest problems: Why immunotherapy still falls short
Cyprium board signs off on Nifty cathode restart, clearing path to mid-2026 production
Archer advances towards single-qubit readout with key device milestone
Orthocell advances Remplir™ prostate surgery opportunity as Australian use surpasses 100 cases
Small Cap Watch: XSO extends declines, but there are company highlights
Archer and EPFL Co-Develop a Single Chip Integrated Pulsed Electron Spin Resonance Microsystem
Archer Materials ushers in use of quantum computing in mobile devices with latest 12CQ chip breakthrough
Archer Materials spinout ChemX Materials floats on the local share market
Archer Materials shares surge after integrating single atom-thick graphene on a silicon wafer
Archer Materials' “special year” sets stage for increasing role in quantum computing
Imugene and Archer Materials benefit from S&P Dow Jones Indices rebalance
Archer Materials develops sensing pathways to detect genetic information for biochip technology
Archer Materials flags priority offer under ChemX IPO
Archer Materials to collaborate with AIML on quantum semiconductor development
Archer Materials' deep tech could be game-changing for two key tech sectors
Archer Materials giving investors exposure to deep-tech
Archer Materials passes key milestone in early-stage assembly of biochip components
Archer Materials raises A$15 million in heavily backed SPP
Archer Materials closing SPP early after exceeding expectations to raise A$10 million
Archer Materials shares rise after early-stage validation of qubit robustness